<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02373124</url>
  </required_header>
  <id_info>
    <org_study_id>7051</org_study_id>
    <nct_id>NCT02373124</nct_id>
  </id_info>
  <brief_title>Glutamatergic Modulation of Motivation Enhancement: A Pilot Feasibility Trial</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the feasibility of a treatment paradigm that involves naturalistic
      cocaine use opportunities in the context of psychotherapy aimed at utilizing these
      opportunities therapeutically.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2014</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cocaine Use, as assessed by urine toxicology and time-line follow back</measure>
    <time_frame>5 weeks</time_frame>
    <description>investigation of whether cocaine use worsens as a result of naturalistic use opportunities; this will be assessed by urine toxicology and time-line follow back</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Cocaine Use Disorders</condition>
  <arm_group>
    <arm_group_label>open-label</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>52 minute infusion of NMDA antagonist</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>infusion of NMDA antagonist</intervention_name>
    <description>52 minute infusion</description>
    <arm_group_label>open-label</arm_group_label>
    <other_name>NMDA antagonist</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criterion Method of Ascertainment

          1. Active cocaine dependence with at least 8 days of use or at least 4 binges of large
             amounts (&gt;$200/occasion) over the past 30 days, and displaying at least one positive
             utox during screening SCID, Psychiatric Interview, self-report, utox

          2. Physically healthy Laboratory tests (urinalysis, blood chemistry, 12-lead ECG in
             normal limits), physical examination, self-reported medical history

          3. No adverse reactions to study medications Subjects will be asked about previous
             exposure to ketamine and midazolam

          4. 21-55 years of age Self-reported age, verification with legal identification

          5. Capacity to consent and comply with study procedures, including sufficient proficiency
             in English A short written test about study procedures, SCID, psychiatric interview

          6. Seeking treatment Psychiatric Interview, self-report

        Exclusion Criterion Method of Ascertainment

          1. Meets DSM IV criteria for current major depression, bipolar disorder, schizophrenia,
             any psychotic illness, including substance induced psychosis, and current
             substance-induced mood disorder with HAMD score &gt; 12. Psychiatric Interview, SCID,
             HAMD

          2. Physiological dependence on another substance, such as alcohol, opioids, or
             benzodiazepines, excluding caffeine, nicotine, and cannabis SCID, Psychiatric
             Interview

          3. Delirium, Dementia, Amnesia, Cognitive Disorders, or Dissociative disorders SCID,
             Psychiatric Interview

          4. Current suicide risk or a history of suicide attempt within the past year SCID,
             Psychiatric Interview

          5. Pregnant or interested in becoming pregnant during the study period Blood and urine
             pregnancy testing, self-report

          6. Any of the following cardiac conditions: clinically significant left ventricular
             hypertrophy, angina, clinically significant arrhythmia, or mitral valve prolapse
             Laboratory tests (12-lead ECG in normal limits), physical examination, self-reported
             medical history

          7. Unstable physical disorders which might make participation hazardous such as end-stage
             AIDS, hypertension (&gt;140/90), WBC &lt; 3.5, active hepatitis or other liver disease with
             elevated transaminase levels (&lt; 2-3 X upper limit of normal will be considered
             acceptable if PT/PTT is normal), renal failure (creat &gt; 2, BUN &gt;40), or untreated
             diabetes Physiological tests (urinalysis, blood chemistry, 12-lead ECG), physical
             examination, self-reported medical history

          8. Previous history of ketamine or midazolam misuse or abuse, and a history of an adverse
             reaction/experience with prior exposure to cocaine, ketamine or midazolam Physical
             examination, self-reported medical history

          9. Recent history of significant violence (past 2 years) SCID, Psychiatric Interview

         10. Abnormal pseudocholinesterase level Blood testing

         11. First degree relative with a psychotic disorder (bipolar disorder, schizophrenia,
             schizoaffective disorder, or psychosis NOS) SCID, Psychiatric Interview

         12. BMI &gt; 35, or a history of documented obstructive sleep apnea Physical examination,
             self-reported medical history

         13. On psychotropic or other medications whose effect could be disrupted by participation
             in the study Psychiatric interview, self-reported medical history

         14. Patients who cannot comply with study procedures during the initial hospitalization
             phase Study Performance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>New York State Psychiatric Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 30, 2015</study_first_submitted>
  <study_first_submitted_qc>February 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2015</study_first_posted>
  <last_update_submitted>August 7, 2017</last_update_submitted>
  <last_update_submitted_qc>August 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

